Effects of anti-RANKL and anti-PD-1 antibodies on cancer-induced osteolysis in mice
{{output}}
Objectives: Denosumab, an anti-bone resorptive agent composed of the anti-receptor activator of nuclear factor-κB ligand (RANKL) monoclonal antibody, and nivolumab, an immune checkpoint inhibitor composed of the anti-programmed ... ...
